Main text {#Sec1}
=========

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer worldwide, accounting for approximately 85% of lung cancers \[[@CR1]\]. Despite achievements in clinical diagnosis and treatment, NSCLC patients have poor survival. Therefore, a better understanding of molecular mechanisms underlying NSCLC could promote discovery of novel therapeutic targets and improve survival.

A subtype of NSCLC harbors *ROS1* fusion genes from aberrant chromosomal translocations of two separated genes. Among them, *SLC34A2-ROS1* fusion gene encodes oncogenic fusion protein to activate downstream signaling cascades such as JAK/STAT, PI3K/Akt and RAS/RAF pathways and promote cell proliferation and survival \[[@CR2]\]. However, the underlying mechanism of *SLC34A2-ROS1* gene during tumorigenesis remains unclear.

Emerging evidences demonstrated that, except for encoding fusion protein, fusion gene could generate circular RNA (circRNA), a covalently-bonded RNA molecule from the back-splicing of linear RNA, to participate in tumor initiation and progression. For example, *PML-RARα* fusion gene produces f-circPR to promote cell growth in acute promyelocytic leukemia, while *MLL-AF9* fusion gene generates f-circM9 that contributes to leukemia progression in vitro and in vivo \[[@CR3]\]. Recently, we found that *EML4-ALK* fusion gene can produce two circRNAs \[[@CR4], [@CR5]\], one of which is a novel liquid biopsy biomarker for lung cancer \[[@CR5]\]. However, whether *SLC34A2-ROS1* gene generates circRNA is unknown. In this study, we identify the novel circRNA F-circSRs generated from *SLC34A2-ROS1* gene. Moreover, F-circSRs, independent from *SLC34A2-ROS1* fusion protein, have little effect on cell proliferation, but promote cell migration in lung cancer cells, highlighting the oncogenic role of F-circSRs in NSCLC.

Results and discussion {#Sec2}
======================

Identification of F-circSR in NSCLC cells {#Sec3}
-----------------------------------------

It is reported that the NSCLC cell line HCC78 harbors two forms of *SLC34A2-ROS1* fusion genes expressing long and short transcripts (*SLC34A2* exon 4 fused to *ROS1* exons 32 and 34, respectively) (Fig. [1](#Fig1){ref-type="fig"}a, b). To verify this, we performed RT-PCR using the convergent primers (F1/R1, Additional file [1](#MOESM1){ref-type="media"}). The Sanger sequencing results confirmed the existence of two *SLC34A2-ROS1* mRNA variants in HCC78 cells, same as the reference sequences EU236946.1 and EU236947.1 in GenBank (Fig. [1](#Fig1){ref-type="fig"}c). Next, we investigated whether *SLC34A2-ROS1* fusion genes generate circRNA. Total RNAs extracted from HCC78 cells were treated with RNase R to remove linear RNAs, and then subjected to RT-PCR using the divergent primers (F2/R2 and F3/R2, respectively). As shown in Fig. [1](#Fig1){ref-type="fig"}d, two circRNAs, designated as F-circSR1 (from longer variant) and F-circSR2 (from shorter variant), were identified by agarose electrophoresis and Sanger sequencing because of the existence of the back-splicing junction between the 5′ head of *SLC34A2* exon 2 and 3′ tail of *ROS1* exon 37 or 42. Moreover, qPCR results showed that F-circSR1 has much higher expression level than F-circSR2 in HCC78 cells (Additional file [2](#MOESM2){ref-type="media"}: Figure S1). Therefore, these data indicate *SLC34A2-ROS1* fusion gene generates two circRNAs in HCC78 cells, with higher F-circSR1 expression.Fig. 1Identification of F-circSR in HCC78 cells. **a\~b** Schematic representation of F-circSR generated from *SLC34A2-ROS1* fusion gene. E means exon. **c** Agarose gel electrophoresis and Sanger sequencing of RT-PCR products from HCC78 cells, the arrows indicate *SLC34A2-ROS1* fusion sites. **d** Identification of F-circSR in HCC78 cells by RT-PCR and Sanger sequencing. The arrows indicate F-circSR junction sites

F-circSRs promote cell migration in NSCLC cells {#Sec4}
-----------------------------------------------

To characterize biological function of F-circSR in NSCLC cells, we constructed F-circSR-overexpressing plasmids with reverse repeat of ciRS-7 intron sequences plus the upstream and downstream flanking intron sequences of F-circSR, which favor circRNA formation (Fig. [2](#Fig2){ref-type="fig"}a). Firstly, the F-circSR-overexpressing plasmids were transiently transfected into HEK293T cells. The successful expression of both F-circSR1 and F-circSR2 and their accurate circularization were confirmed by agarose electrophoresis and Sanger sequencing (Fig. [2](#Fig2){ref-type="fig"}b). Then we chose H1299 and A549 cells to generate stable cells correctly expressing F-circSRs because both cells don't express *SLC34A2-ROS1* fusion protein (Fig. [2](#Fig2){ref-type="fig"}c, Additional file [2](#MOESM2){ref-type="media"}: Figure S2a). Transwell migration assays show that both F-circSRs significantly promoted cell migration in both cells (Fig. [2](#Fig2){ref-type="fig"}d), which were further confirmed by wound healing assays (Fig. [2](#Fig2){ref-type="fig"}e, f). However, MTT assays and colony formation experiments indicated that both F-circSRs have little effect on cell proliferation (Additional file [2](#MOESM2){ref-type="media"}: Figure S2b, S2c). To avoid the bias caused by circRNA expression plasmid, we employed our previously reported expression system \[[@CR4]\]. And the results confirmed again that F-circSRs promote cell migration in NSCLC cells (Additional file [2](#MOESM2){ref-type="media"}: Figure S3).Fig. 2F-circSR promotes cell migration in NSCLC cells. **a** Schematic representation of pCRE5-F-circSR-expressing plasmid. **b** Agarose gel electrophoresis and Sanger sequencing of RT-PCR products from HEK293T cells transfected with F-circSR-expressing plasmid or empty vector. **c** Agarose gel electrophoresis of RT-PCR products from A549 and H1299 cells stably expressing F-circSR. **d** Representative images of Transwell migration assays and quantification in A549 and H1299 cells with or without F-circSR overexpression. **e\~f** Representative images of wound healing assays in H1299 and A549 cells with or without F-circSR overexpression. **g\~h** F-circSR knockdown attenuates the migratory ability in F-circSR1 (g) or F-circSR2 (h) overexpressing H1299 cells. SR1: F-circSR1; SR2: F-circSR2; E: exon

Besides gain-of-function experiments, the loss-of-function strategy was also used to examine cellular function of F-circSR. The small interfering RNAs (siRNAs) targeting the back-splicing junction of circRNAs were designed to efficiently knock down F-circSR expression (Additional file [2](#MOESM2){ref-type="media"}: Figure S2d, S2e). Transwell migration assays showed that silencing of F-circSR significantly decreased the cell migratory ability in F-circSR-overexpressing H1299 (Fig. [2](#Fig2){ref-type="fig"}g, h) and A549 cells (Additional file [2](#MOESM2){ref-type="media"}: Figure S2f-S2 h), convincing the role of F-circSR in promoting cell migration in NSCLC cells.

It is well documented that *SLC34A2-ROS1* fusion gene encodes the fusion protein to participate in tumorigenesis by activating ROS1 signaling \[[@CR2]\]. Our findings suggest that except for encoding fusion protein, *SLC34A2-ROS1* fusion gene may exert its oncogenic role through generating circRNAs. Moreover, we performed bioinformatics analysis to find that F-circSRs harbor the binding sites of miR-150-5p, miR-194-3p and miR-515-5p that have been reported to regulate cell migration. So F-circSR may act as miRNA sponge to exert its function (Additional file [2](#MOESM2){ref-type="media"}: Figure S4). Giving that circRNA could be a potential biomarker due to its higher stability in body fluids, the diagnostic potential of F-circSR for lung cancer needs further investigation.

The complementary sequences in flanking introns are important for F-circSR biogenesis {#Sec5}
-------------------------------------------------------------------------------------

Similar to most circRNAs, both F-circSRs consist of multiple exons. CircRNA biogenesis depends on the cis-regulatory elements that reside in the flanking introns of circularized exons, usually containing reverse complementary sequences \[[@CR6], [@CR7]\]. Bioinformatics analysis revealed that the flanking introns of both F-circSRs have reverse complementary sequences (designated as CS1 and CS2), while the CS1-CS2 complementarity in F-circSR1 is stronger than that in F-circSR2 due to the longer matching sequence (Fig. [3](#Fig3){ref-type="fig"}a, Additional file [3](#MOESM3){ref-type="media"}). Next we subcloned these sequences into the minigene GFP reporter system containing a single exon encoding split GFP in reverse order (Fig. [3](#Fig3){ref-type="fig"}b, Additional file [4](#MOESM4){ref-type="media"}), which does not express normal GFP protein unless inserted sequences back splice to produce a circRNA \[[@CR8]\]. Additionally, we also constructed the plasmids with the mutation of splicing sites (from "AG" to "TT", M1 plasmid) or deletion of the downstream complementary sequence (M2 plasmid) (Fig. [3](#Fig3){ref-type="fig"}b). As shown in Fig. [3](#Fig3){ref-type="fig"}c, inserted normal CS1 and CS2 sequences from either F-circSR can drive circRNA formation to express GFP protein, with the sequences from F-circSR1 showing stronger activity than those from F-circSR2, consistent with the higher CS1-CS2 complementarity in F-circSR1 from bioinformatics data. So stronger pairing of longer sequences considerably enhances circRNA production. However, destroying the splicing sites or complementary sequences of F-circSRs blocks circRNA formation, thus lacking GFP expression (Fig. [3](#Fig3){ref-type="fig"}c). These conclusions were further confirmed by Western blotting and flow cytometry analyses (Fig. [3](#Fig3){ref-type="fig"}d, e). Therefore, the flanking complementary sequences with canonical splicing sites are important for F-circSR formation.Fig. 3The flanking complementary sequences are important for F-circSR biogenesis. **a** Bioinformatics analysis of the cis-elements in the flanking introns of F-circSR. CS: upstream and downstream sequences of F-circSR; SA, splicing acceptor; SD, splicing donor. The circle denotes the junction site. The grey boxes called P indicate complementary sequences. **b** Schematic representation of GFP-based reporters to examine essential elements for circRNA formation. **c\~e** GFP detection through fluorescence microscope **(c)**, flow cytometry **(d)** and Western blot **(e)**

Conclusions {#Sec6}
===========

In this study, we identified two novel circRNAs (designated as F-circSR1 and F-circSR2) generated from *SLC34A2-ROS1* fusion gene in NSCLC cells, with higher expression of F-circSR1 than F-circSR2, whose formation depends on their flanking complementary sequences with canonical splicing sites. Moreover, both F-circSRs can significantly promote cell migration. Therefore, our study not only expands the current knowledge of chromosomal translocations in cancer biology, but also provides potential diagnostic and therapeutic biomarker.
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Additional file 1:Information about primers, siRNAs and full sequence of F-circSR. (DOCX 40 kb) Additional file 2:**Figure S1.** Absolute quantification of F-circSRs in HCC78 cells using qPCR. **Figure S2.** Characterization of cellular function of F-circSR in lung cancer cells. **Figure S3.** Validation of cellular function of F-circSR using pLaccase2 circRNA expression system. **Figure S4.** Predicted miRNA biding sites in F-circSRs. (DOCX 2870 kb) Additional file 3:Bioinformatics analysis of the cis-elements in the flanking introns of F-circSR. (DOCX 1084 kb) Additional file 4:Supplementary Materials and Methods. (DOCX 2750 kb)
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